Belviq Recall Lawyers Investigating Weight Loss Drug Cancer Claims
On February 13, the U.S. Food and Drug Administration announced that a Belviq recall should be issued to remove the popular weight loss drug from the market, after post-marketing clinical trials identified a cancer risk for users.
As a result, the product liability lawyers at Saiontz & Kirk, P.A. are now reviewing Belviq lawsuits for former users diagnosed with:
- Pancreatic Cancer
- Lung Cancer
- Colorectal Cancer
- Other Digestive Cancers
It appears that individuals throughout the United States may have avoided cancer if the drug maker had adequately researched the side effects of Belviq and warned about the risk of cancer. As a result substantial compensation may be available.
Contact Saiontz & Kirk, P.A. today to review whether you or a loved one may have a claim. There are no fees or expenses unless a recovery or Belviq settlement is obtained.
Belviq and Belviq XR Removed From Market
Belviq (lorcaserin) was approved by the FDA in 2012 and has been marketed as a safe and effective weight loss drug, which is designed to give users the feeling of being full. However, even before the drug was introduced, there were widespread concerns about the safety of Belviq.
As early as June 2012, the consumer watchdog group Public Citizen issued a statement warning that the drug maker was ignoring important safety data and predicting that Belviq would be recalled within a few years.
The group noted that several similar weight loss drug recalls have been issued in prior years, including Fen-Phen, Dexatrim, Accutrim and Meridia. While Public Citizen suggested that heart risks would lead to the recall of Belviq, it turns out the problems are much more serious, and users may face an increased risk of several different types of cancer.
In January 2020, the FDA issued a drug safety communication after receiving data from a post-marketing study conducted by the drug maker, which followed 12,000 individuals given Belviq or a placebo.
Just a month later, the FDA recommended that the drug maker remove Belviq from the market and urged consumers to stop using the weight loss drug after determining that there was an imbalance in the number of cancers among users of the active drug.
The median follow up time was 3 years and 3 months, and among the findings:
- One additional cancer diagnosis was found per 470 patients treated with Belviq for one year;
- 7.7% of Belviq users were diagnosed with cancer, compared to 7.1% of users from the placebo group;
- Pancreatic cancer, colorectal cancer and lung cancer were identified as specific cancers that resulted in the imbalance;
- The imbalance in cancer diagnosed increased the longer Belviq was used.
Belviq Cancer Claims
The product liability lawyers at Saointz & Kirk, P.A. are reviewing potential claims nationwide for individuals diagnosed with cancer that may be caused by Belviq side effects.
Individual cancer lawsuits, as well as Belviq recall class action and wrongful death claims are being investigated, as it appears that many cancer cases may have been avoided if the drug maker had adequately researched the diet drug and warned doctors and consumers about the health risks.
To review whether you or a loved one may have a claim, request a free consultation and claim evaluation.